Emagliflozin S 25/100

Emagliflozin S 25/100 is a combination oral antidiabetic medicine containing Empagliflozin (25 mg), an SGLT2 inhibitor, and Sitagliptin (100 mg), a DPP-4 inhibitor. This advanced dual therapy is used for the management of Type 2 Diabetes Mellitus (T2DM) in adults who require better blood sugar control than with a single agent alone.

• Empagliflozin 25 mg: Works by increasing glucose excretion through urine, helping to lower blood sugar and support weight loss.

• Sitagliptin 100 mg: Improves the body’s natural insulin response after meals and decreases excess glucose production.

This powerful combination not only lowers fasting and postprandial glucose levels but also helps in reducing HbA1c levels while offering cardiovascular and renal protective benefits.

Key Benefits:

• Dual-action therapy for effective Type 2 Diabetes management

• Helps lower blood sugar and maintain HbA1c levels within target range

• Supports weight management and reduces diabetes-related risks

• Provides cardio-renal benefits in patients with diabetes

• Convenient once-daily tablet with low risk of hypoglycemia